Gene Expression Analysis of Membrane Transporters and Drug-metabolizing Enzymes in the Lung of Healthy and COPD Subjects

Overview

Journal Pharmacol Res Perspect

Date 2014 Dec 16

PMID 25505599

Citations 17

Authors

Tove Berg

Tove Hegelund Myrback

Marita Olsson

Janeric Seidegard

Viktoria Werkstrom

Xiao-Hong Zhou

Johan Grunewald

Lena Gustavsson

Magnus Nord

Affiliations

Soon will be listed here.

Abstract

This study describes for the first time the expression levels of genes encoding membrane transporters and drug-metabolizing enzymes in the lungs of ex-smoking patients with chronic obstructive pulmonary disease (COPD). Membrane transporters and drug-metabolizing enzymes are key determinants of drug uptake, metabolism, and elimination for systemically administered as well as inhaled drugs, with consequent influence on clinical efficacy and patient safety. In this study, while no difference in gene expression was found between healthy and COPD subjects, we identified a significant regional difference in mRNA expression of both membrane transporters and drug-metabolizing enzymes between central and peripheral tissue in both healthy and COPD subjects. The majority of the differentially expressed genes were higher expressed in the central airways such as the transporters SLC2A1 (GLUT1), SLC28A3 (CNT3), and SLC22A4 (OCTN1) and the drug-metabolizing enzymes GSTZ1, GSTO2, and CYP2F1. Together, this increased knowledge of local pharmacokinetics in diseased and normal lung may improve modeling of clinical outcomes of new chemical entities intended for inhalation therapy delivered to COPD patients. In addition, based on the similarities between COPD and healthy subjects regarding gene expression of membrane transporters and drug-metabolizing enzymes, our results suggest that clinical pharmacological studies in healthy volunteers could be a valid model of COPD patients regarding drug disposition of inhaled drugs in terms of drug metabolism and drug transporters.

Citing Articles

Enhancers regulate genes linked to severe and mild childhood asthma.

Akhter T, Mileti E, Kere M, Kolmert J, Konradsen J, Hedlin G Heliyon. 2024; 10(14):e34386.

PMID: 39108895 PMC: 11301366. DOI: 10.1016/j.heliyon.2024.e34386.

Impact of Nebulization on the Physicochemical Properties of Polymer-Lipid Hybrid Nanoparticles for Pulmonary Drug Delivery.

Gonsalves A, Menon J Int J Mol Sci. 2024; 25(9).

PMID: 38732246 PMC: 11084240. DOI: 10.3390/ijms25095028.

Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.

Dong L, Zhuang X Int J Mol Sci. 2024; 25(9).

PMID: 38731891 PMC: 11083391. DOI: 10.3390/ijms25094671.

Epigenome-wide association study of total nicotine equivalents in multiethnic current smokers from three prospective cohorts.

Huang B, Binder A, Quon B, Patel Y, Lum-Jones A, Tiirikainen M Am J Hum Genet. 2024; 111(3):456-472.

PMID: 38367619 PMC: 10940014. DOI: 10.1016/j.ajhg.2024.01.012.

Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression.

Amgalan B, Day C, Przytycka T PLoS Comput Biol. 2023; 19(9):e1011472.

PMID: 37721939 PMC: 10538798. DOI: 10.1371/journal.pcbi.1011472.

References

Darquenne C . Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012; 25(3):140-7. PMC: 3417302. DOI: 10.1089/jamp.2011.0916. View

Hallgren O, Nihlberg K, Dahlback M, Bjermer L, Eriksson L, Erjefalt J . Altered fibroblast proteoglycan production in COPD. Respir Res. 2010; 11:55. PMC: 2886021. DOI: 10.1186/1465-9921-11-55. View

Bauer M, Herbarth O, Aust G, Hengstler J, Dotzauer A, Graebsch C . Expression patterns and novel splicing variants of glutathione-S-transferase isoenzymes of human lung and hepatocyte cell lines. Cell Tissue Res. 2006; 324(3):423-32. DOI: 10.1007/s00441-005-0150-8. View

Kim J, Sherman M, Curriero F, Guengerich F, Strickland P, Sutter T . Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol. 2004; 199(3):210-9. DOI: 10.1016/j.taap.2003.11.015. View

Raunio H, Hakkola J, Hukkanen J, Lassila A, Paivarinta K, Pelkonen O . Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol. 1999; 51(4-5):412-7. DOI: 10.1016/S0940-2993(99)80031-1. View

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh J, Tamai I . Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2009; 7(1):187-95. DOI: 10.1021/mp900206j. View

Bandi N, Kompella U . Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol. 2002; 437(1-2):9-17. DOI: 10.1016/s0014-2999(02)01267-0. View

Seree E, Villard P, Hever A, Guigal N, Puyoou F, Charvet B . Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun. 1998; 252(2):392-5. DOI: 10.1006/bbrc.1998.9662. View

10.

Ding X, Kaminsky L . Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2002; 43:149-73. DOI: 10.1146/annurev.pharmtox.43.100901.140251. View

11.

Budulac S, Postma D, Hiemstra P, Lapperre T, Kunz L, Vonk J . Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD. Eur J Pharmacol. 2012; 696(1-3):136-42. DOI: 10.1016/j.ejphar.2012.08.015. View

12.

Leclerc J, Courcot-Ngoubo Ngangue E, Cauffiez C, Allorge D, Pottier N, Lafitte J . Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie. 2011; 93(6):1012-27. DOI: 10.1016/j.biochi.2011.02.012. View

13.

Patton J, Byron P . Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2006; 6(1):67-74. DOI: 10.1038/nrd2153. View

14.

Zhang J, Wang Y, Prakash C . Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 2006; 7(8):939-48. DOI: 10.2174/138920006779010575. View

15.

Hukkanen J, Pelkonen O, Hakkola J, Raunio H . Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002; 32(5):391-411. DOI: 10.1080/20024091064273. View

16.

Hallgren O, Rolandsson S, Andersson-Sjoland A, Nihlberg K, Wieslander E, Kvist-Reimer M . Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients. J Transl Med. 2012; 10:171. PMC: 3477051. DOI: 10.1186/1479-5876-10-171. View

17.

Aitken A, Richardson T, Morgan E . Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006; 46:123-49. DOI: 10.1146/annurev.pharmtox.46.120604.141059. View

18.

Storey J, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003; 100(16):9440-5. PMC: 170937. DOI: 10.1073/pnas.1530509100. View

19.

Bleasby K, Castle J, Roberts C, Cheng C, Bailey W, Sina J . Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica. 2006; 36(10-11):963-88. DOI: 10.1080/00498250600861751. View

20.

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270(1):414-23. View